Clinical Trial

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

Name: Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases — clinical trial record (NCT06440954)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EPIC

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a prospective interventional study clinical study to investigate the efficacy and resistance mechanisms of intrathecal pemetrexed in patients with driver gene mutations advanced NSCLC with leptomeningeal metastases.

Trial Details

NCT Number	NCT06440954
Lead Sponsor	Hunan Province Tumor Hospital Collaborators: Hunan Cancer Hospital
Conditions	Non-Small Cell Lung Cancer
Enrollment	220 participants
Start Date	2024-05-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2024-06-04